Sign in
Taking people in United StatesNo phase

Observes patients with heart failure using the WiSE System device

Watches how the WiSE device performs in adults with heart failure.

Key facts

Who runs it
EBR Systems, Inc.
Where
Ann Arbor, Austin, Charleston, Charlottesville, Cleveland, Hershey, Jonesboro, Kansas City, Mesa, Naples, New York, and Scottsdale, United StatesSee the 12 sites
Trial code
Registry title
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
Status
Recruiting
People taking part
320 people, planned
Started
3 Nov 2025
Expected to end
30 Sept 2032
Type of study
Observational
Treatments tested
  • The Wise System
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure who are planned to receive the WiSE System and passed the acoustic window screening.

Age
22 years or older
Sex
All sexes can join

Main reasons for not taking part

  • Not planning to receive a WiSE System or did not pass the acoustic window screening
  • Taking part in another drug or device study that could confuse the results
  • Life expectancy of 1 year or less
  • Not able to be reached for follow-up
  • Cannot give written consent, or taking part is not allowed by local law

The registry criteria, word for word

Show all 6 criteriaShow less

Other criteria

  • Patient or legally authorized representative can provide written authorization and/or consent per institution requirements
  • Patient is intended to receive a WiSE System and passed the acoustic window screening
  • Patient who is, or will be, accessible for follow-up
  • Participation is not excluded by local law
  • Patient is not enrolled in a concurrent drug and/or device study that may confound the Registry results
  • Patient life expectancy >1 year

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Kirsta BrayTaking people
  • Texas Cardiac Arrhythmia Research FoundationAustin, United StatesContact: Deb CardinalTaking people
  • MUSCCharleston, United StatesContact: Krista SzymanskiTaking people
  • UVACharlottesville, United StatesContact: Abbey FergusonTaking people
  • Cleveland Clinic FoundationCleveland, United StatesContact: Danielle LiggettTaking people
  • Penn State HealthHershey, United StatesContact: LIsa FoxTaking people
  • Arrhythmia Research Group (St. Bernards Hospital)Jonesboro, United StatesContact: Kayla RubinoTaking people
  • St. Luke's Hospital of Kansas CityKansas City, United StatesContact: Susan EhlertTaking people
  • CardioVascular Associates of Mesa (CVAM)Mesa, United StatesContact: Adam GitkinTaking people
  • Naples Community HospitalNaples, United StatesContact: Linda PastoriousTaking people
  • Weill Cornell MedicineNew York, United StatesContact: Ruwanthi J PereraTaking people
  • Honor HealthScottsdale, United StatesContact: Kathrina SpencerTaking people

About the trial

What the trial wants to find out

Observe to understand product performance, including patient safety, clinical outcomes, and CRT response information associated with the use of the market-released WiSE System

The group in the trial

  • Single-arm, prospective, multicenter, observational study.

    Market-released WiSE System approved for commercial release with a market-released co-implanted system are eligible.

    Treatment: The Wise System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
Plain-language title
Observes patients with heart failure using the WiSE System deviceGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
16 October 2026